Skip to main content

Tolinase Side Effects

Generic name: tolazamide

Medically reviewed by Last updated on Jun 6, 2023.

Note: This document contains side effect information about tolazamide. Some dosage forms listed on this page may not apply to the brand name Tolinase.

Applies to tolazamide: oral tablet.

Serious side effects of Tolinase

Along with its needed effects, tolazamide (the active ingredient contained in Tolinase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tolazamide:


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking tolazamide:

Symptoms of overdose

Other side effects of Tolinase

Some side effects of tolazamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common


Incidence not known

For Healthcare Professionals

Applies to tolazamide: oral tablet.


The most commonly reported adverse reactions have included gastrointestinal disturbances such as nausea, epigastric fullness, and heartburn.[Ref]


Very rare (less than 0.01%): Disulfiram-like reactions

Frequency not reported: Hypoglycemia


Frequency not reported: Hepatic porphyria[Ref]


Common (1% to 10%): Nausea, epigastric fullness, heartburn[Ref]

Gastrointestinal disturbances such as nausea, epigastric fullness, and heartburn tend to be dose related and may disappear when dosage is reduced.[Ref]



Frequency not reported: Increased cardiovascular mortality[Ref]

In the University Group Diabetes Program (UGDP) study, cardiovascular mortality rate was approximately 2.5 times higher in patients treated for 5 to 8 years with diet plus tolbutamide 1.5 g per day compared with that of patients treated with diet alone. The UGDP study was a long-term prospective clinical trial designed to evaluate the effectiveness of glucose lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes mellitus (n=823). Tolbutamide was stopped based on the increase in cardiovascular mortality; a significant increase in total mortality was not observed, but stopping the drug may have limited the ability to measure that. In view of the close similarities in mode of action and chemical structure among sulfonylureas, these results may apply to other drug in this class.[Ref]


Frequency not reported: Hypersensitivity reactions[Ref]

Hypersensitivity reactions described as skin reactions, e.g. pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 0.4% of patients during clinical trials. These may be transient and may disappear despite continued therapy; however, if skin reactions persist, this drug should be discontinued.[Ref]

Nervous system

Uncommon (0.1% to 1%): Dizziness, headache, weakness[Ref]


Rare (less than 0.1%): Cholestatic jaundice[Ref]


Frequency not reported: Hyponatremia


Frequency not reported: Syndrome of inappropriate antidiuretic hormone (SIADH) secretion[Ref]


Uncommon (0.1% to 1%): Fatigue, malaise, vertigo[Ref]



Rare (less than 0.1%): Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia


Uncommon (0.1% to 1%): Allergic skin reactions (pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions)


Frequency not reported: Photosensitivity, porphyria cutanea tarda[Ref]


1. (2016) "Product Information. Tolazamide (tolazamide)." Mylan Pharmaceuticals Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.